Mineralys Therapeutics (MLYS) Free Cash Flow (2022 - 2026)
Mineralys Therapeutics (MLYS) reported Free Cash Flow of -$39.5 million for Q1 2026, up 13.23% on a YoY basis from -$34.9 million in Q1 2025, and down 4.06% sequentially from -$37.9 million in Q4 2025.
Mineralys Therapeutics (MLYS) Free Cash Flow (2022 - 2026) Analysis & Trends
Mineralys Therapeutics (MLYS) has 5 years of Free Cash Flow data on file, last reported at -$39.5 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow rose 13.23% year-over-year to -$39.5 million; the trailing twelve-month figure through Mar 2026 stood at -$136.4 million (up 29.21% YoY), and the FY2025 full-year result was -$142.4 million, up 14.41% from the prior year.
- Free Cash Flow fell to -$39.5 million in Q1 2026, from -$37.9 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$5.5 million in Q2 2022 to a low of -$66.8 million in Q4 2024.
- A 5-year average of -$27.0 million and a median of -$28.8 million in 2025 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow tumbled 272.76% in 2023 and soared 43.25% in 2025, its largest moves.
- Tracing MLYS's Free Cash Flow over 5 years: stood at -$10.2 million in 2022, then tumbled by 184.52% to -$29.0 million in 2023, then tumbled by 130.64% to -$66.8 million in 2024, then soared by 43.25% to -$37.9 million in 2025, then fell by 4.06% to -$39.5 million in 2026.
- Business Quant data shows MLYS's Free Cash Flow at -$39.5 million in Q1 2026, -$37.9 million in Q4 2025, and -$28.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Mineralys Therapeutics | 2.24 Bn | 2.24 Bn | - | -39.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.47 Mn |
| Mar 31, 2026 | -39.47 Mn |
| Dec 31, 2025 | -37.93 Mn |
| Dec 31, 2025 | -37.93 Mn |
| Sep 30, 2025 | -28.80 Mn |
| Sep 30, 2025 | -28.80 Mn |
| Jun 30, 2025 | -30.21 Mn |
| Jun 30, 2025 | -30.21 Mn |
| Mar 31, 2025 | -45.49 Mn |
| Mar 31, 2025 | -45.49 Mn |
| Dec 31, 2024 | -66.84 Mn |
| Dec 31, 2024 | -66.84 Mn |
| Sep 30, 2024 | -50.22 Mn |
| Sep 30, 2024 | -50.22 Mn |
| Jun 30, 2024 | -30.15 Mn |
| Jun 30, 2024 | -30.15 Mn |
| Mar 31, 2024 | -19.20 Mn |
| Mar 31, 2024 | -19.20 Mn |
| Dec 31, 2023 | -28.98 Mn |
| Dec 31, 2023 | -28.98 Mn |